Today, the VP Finance of Pacira Pharmaceuticals (NASDAQ: PCRX), Lauren Bullaro Riker, sold shares of PCRX for $74.15K.
Following Lauren Bullaro Riker’s last PCRX Sell transaction on June 06, 2018, the stock climbed by 8.8%.
See today’s analyst top recommended stocks >>
Based on Pacira Pharmaceuticals’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $84.11 million and quarterly net profit of $2.56 million. In comparison, last year the company earned revenue of $70.93 million and had a GAAP net loss of $19.74 million. Currently, Pacira Pharmaceuticals has an average volume of 369.7K.
Based on 14 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $51.33, reflecting a 11.1% upside. Three different firms, including BMO Capital and Merrill Lynch, currently also have a Sell rating on the stock.
The insider sentiment on Pacira Pharmaceuticals has been negative according to 31 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
